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Little is known about the role of Abs in determining the outcome
of hepatitis C virus (HCV) infection. By using infectious retroviral
pseudotypes bearing HCV glycoproteins, we measured neutraliz-
ing Ab (nAb) responses during acute and chronic HCV infection. In
seven acutely infected health care workers, only two developed a
nAb response that failed to associate with viral clearance. In
contrast, the majority of chronically infected patients had nAbs. To
determine the kinetics of strain-specific and crossreactive nAb
emergence, we studied patient H, the source of the prototype
genotype 1a H77 HCV strain. An early weak nAb response, specific
for the autologous virus, was detected at seroconversion. How-
ever, neutralization of heterologous viruses was detected only
between 33 and 111 weeks of infection. We also examined the
development of nAbs in 10 chimpanzees infected with H77 clonal
virus. No nAb responses were detected in three animals that
cleared virus, whereas strain-specific nAbs were detected in six of
the seven chronically infected animals after 50 weeks of infec-
tion. The delayed appearance of high titer crossreactive nAbs in
chronically infected patients suggests that selective mechanism(s)
may operate to prevent the appearance of these Abs during acute
infection. The long-term persistence of these nAbs in chronically
infected patients may regulate viral replication.
Hepatitis C virus (HCV) is an enveloped positive-strandedRNA virus classified in the Flaviviridae family. An esti-
mated 170 million individuals are infected with HCV worldwide.
The acute phase of infection is often subclinical, and 70% of
individuals develop a chronic infection that may result in pro-
gressive liver disease. The high frequency of chronic infection
suggests that an effective antiviral immune response is not
initiated or maintained and that virus-mediated immune escape
strategies may be operating. Although the mechanisms leading
to clearance versus viral persistence are not clearly defined, there
is growing evidence from studies in humans and chimpanzees
that an early and strong intrahepatic CD4 and CD8 cell
response is associated with viral clearance (1, 2).
Neutralizing Ab (nAb) responses after natural infection or
vaccination comprise a major component of protection from
virus infection (3). However, the role of nAbs in HCV infection
and disease progression are unclear, largely because of the lack
of assays to measure and quantify their activity. A hypervariable
region (HVR) in the E2 envelope glycoprotein (gp) has been
proposed to be a target for nAbs (4, 5), and studies on the rate
of HVR evolution suggest that variation is a function of the
immune pressure exerted by the Ab response (6, 7). Previous
experiments showed that serum from a chronically infected
patient could neutralize HCV infectivity in a chimpanzee model,
suggesting the presence of nAbs (4). In the absence of a
cell-culture system capable of generating infectious HCV parti-
cles, truncated soluble version(s) of the viral encoded gps have
been used to study virus–cell interactions (8). Rosa et al. (9)
reported that the presence of Abs that could inhibit soluble E2
gp binding to cells associated with viral clearance in immunized
animals; however, the relevance of such blocking Abs to neu-
tralization is unknown.
The recent development of infectious retroviral HCV
pseudotypes, comprising HIV capsids bearing HCV envelope
gps, have allowed the study of nAbs during HCV infection (10,
11). Bartosch et al. (12) recently validated this system, reporting
an association between samples able to neutralize HCV
pseudotypes and those able to inhibit HCV infection of chim-
panzees. nAbs can be classified as strain-specific, showing a
restricted neutralization of autologous virus, or crossreactive,
being able to neutralize both autologous and heterologous
viruses. In this study, we demonstrate that the majority of
chronically infected patients have high-titer, crossreactive nAb
responses. In contrast, crossreactive nAbs were detected in only
two of seven acutely infected patients, and their presence failed
to associate with viral clearance. We studied the response in
chronically infected patient H, from whom the prototype geno-
type 1a H77 HCV strain was cloned. Interestingly, this patient
developed a strain-specific nAb response at seroconversion that
only broadened to neutralize other viral strains between 33 and
111 weeks after infection. Because the chimpanzee is the only
animal model currently available for HCV vaccine studies, we
compared the nAb response in animals infected with clonal H77
virus. The majority of infected chimpanzees developed a low-
titer, strain-specific nAb response late in disease, which failed to
associate with viral clearance. In most viral infections, nAbs are
generally considered to ‘‘blunt’’ viral replication, allowing CD4
and CD8 T cell responses to clear virus-infected cells (3). It may
be a critical mechanism of HCV persistence that crossreactive
nAb responses are delayed until a time when the cellular immune
response is dysfunctional and unable to clear infected cells. If so,
strategies to induce such a nAb response during the immuno-
competent acute phase of infection may have beneficial effects
in controlling viral replication.
Materials and Methods
Cells and Preparation of Plasma. 293T and Hep3B cells were
propagated in DMEM with 10% FBS. IgG depletion was per-
formed by using the Aurum serum protein kit (Bio-Rad),
designed for the simultaneous removal of albumin and IgG from
plasma. IgG was purified from human plasma by using a HiTrap
Affinity Protein G column (Amersham Pharmacia) and was
quantified by using a human IgG ELISA kit (Bethyl Laborato-
ries, Montgomery, TX).
This paper was submitted directly (Track II) to the PNAS office.
Abbreviations: HCV, hepatitis C virus; gp, glycoprotein; nAb, neutralizing Ab; HVR, hyper-
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Pseudotype Production and Infection. Pseudotypes were generated
by transfection of 293T cells with pNL4-3.Luc.RE plasmid
containing the env-defective HIV proviral genome and an
expression plasmid encoding the HCV gps (strains H, H77,
HCJ4, and HCJ6) or murine leukemia virus (MLV) envelope gp,
as described in refs. 11 and 13. The virus containing extracellular
media was collected 48–72 h after transfection.
Heat-inactivated plasma and virus were mixed at their appro-
priate dilution in 3% FBSDMEM plus 4 gml polybrene and
incubated at 37°C for 1 h. Virusplasma mix was transferred to
Hep3B cells seeded in 96-well plates (8  103 cells per well).
Infections with HIV-HCV HCJ4 and HIV-HCV HCJ6 were
centrifuged at 400  g for 1 h and incubated at 37°C for 6 h;
unbound virus was removed and incubated for a total of 72 h.
Cells were lysed with cell lysis buffer (Promega) and tested for
luciferase activity as described in ref. 11. The percentage neu-
tralization was determined by comparing pseudotype infectivity
[luciferase relative light units (RLU)] in the presence of a test
plasma with infection in the presence of a control HCV-negative
plasma at the same dilution. The luciferase signal standard error
was 25%, such that neutralization values 50% were consid-
ered significant. The ID50 and ID90 values refer to the dilution
of plasma inhibiting pseudotype infectivity by 50% and 90%,
respectively.
Measurement of HCV Viral RNA Levels. Total RNA was prepared
from 100 l of chimpanzee plasma by using TRIzol reagent (Life
Technologies, Gaithersburg, MD), and HCV RNA levels were
quantified by real-time PCR with the PRISM 7700 sequence
detection system (PE Applied Biosystems) (detection threshold,
300 RNA copies per ml) as described in refs. 14 and 15.
Measurement of Anti-NS3 and Anti-E1E2 Ab Responses. Enzyme
immunoassay plates were coated with purified NS3, E1E2 gp, or
a biotinylated peptide (polyprotein amino acids 384–410) rep-
resenting the HVR and tested for immune reactivity with patient
and chimpanzee plasma. Bound immunoglobulins were realized
with horseradish peroxidase-conjugated anti-human IgG or IgM
as described in ref. 16. Mean optical density (OD) values were
expressed as positivenegative (PN) ratios, calculated by divid-
ing the OD of a test sera by that obtained for a preimmune or
irrelevant HCV-negative human serum. The cutoff value was
taken as PN  2.
Results
HCV-Specific nAb Response. To determine whether nAbs are
elicited during infection, plasma samples from uninfected
individuals and from those infected with diverse HCV geno-
types were screened for their ability to inhibit HCV
pseudotype infection. As a specificity control, all plasma
samples were tested for neutralization of pseudotypes bearing
an MLV envelope gp. Independent of their infecting genotype
or viral RNA load, the majority of samples from chronically
infected individuals neutralized HCV pseudotypes bearing
strains H and H77 gps (genotype 1a) (Fig. 1 shows pseudotype
infectivity in the presence of test plasma, and Table 1 shows the
percentage neutralization of each plasma for the viruses
tested). Plasma from uninfected individuals had no effect on
HCV pseudotype infectivity (Fig. 1 and data not shown). All
plasma samples had no effect on HIV-MLV pseudotype
infectivity, confirming the specificity of the neutralizing re-
sponse for viruses bearing HCV gps (Fig. 1). Heat treatment
of the plasma to inactivate complement had no effect on the
ability of plasma to neutralize HCV pseudotype infectivity
Fig. 1. HCV-specific nAb response. (A) Plasma samples from uninfected individuals (cont 1 and cont 2) and those chronically infected with HCV genotypes 1,
2, 3, and 4, with low (, 103 copies per ml) and high (, 103 copies per ml) viral RNA levels, were tested for their ability to neutralize pseudotype viruses
bearing H (HIV-HCV H) and MLV (HIV-MLV) gps at plasma dilutions of 1200 and 11,000. The graph depicts infectivity, expressed as luciferase RLU, of HIV-HCV
H and HIV-MLV (RLU 10) in the presence of various plasma levels. Values are the mean of quadruplicate wells with the standard deviation shown. (B) Plasma
from two chronically HCV-infected (79 and 552) individuals were tested for neutralization of HIV-HCV H at final dilutions of 1200 and 11,000 before and after
depletion of IgG. As a specificity control, virus infection in the presence of plasma from an uninfected individual (cont 1) is shown. Virus infectivity is shown as
RLU, and values are the mean of quadruplicate wells with the standard deviation shown. (C) Neutralization of HIV-HCV H by plasma IgG purified from chronically
infected patient 552. Data are shown as percentage neutralization, derived from quadruplicate wells with the standard deviation shown.
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(data not shown). To study the crossreactive nature of the nAb
response, plasma samples were screened for neutralization of
pseudotypes bearing HCJ4 and HCJ6 gps of genotypes 1b and
2a, respectively. Both of these pseudotypes appeared less
sensitive to neutralization than HIV-HCV H77 (Table 1).
However, similar patterns of neutralization were observed for
all HCV pseudotypes, with some plasma neutralizing certain
pseudotypes more efficiently than others; no genotype-
dependent pattern of neutralization was observed (Table 1).
To confirm that the inhibitory activity of plasma from
chronically infected individuals was mediated by Ig, we ana-
lyzed the effect of depleting IgG from plasma on its ability to
neutralize HCV pseudotypes and the ability of purified plasma
IgG to neutralize HCV pseudotypes. Depletion of IgG from
the plasma of two chronically infected individuals significantly
reduced the neutralization of HIV-HCV H infection, and this
finding associated with the loss of anti-HCV E1E2 reactivity
(Fig. 1B and data not shown). Plasma IgG purified from
HCV-infected patient 552 demonstrated specific neutraliza-
tion of HIV-HCV H infection in a dose-dependent relation-
ship, confirming the Ab-dependent nature of the neutralizing
activity in this sample (Fig. 1C).
Development of nAbs During Acute Infection. To address whether
nAb activity associates with immune control of HCV infection
and viral clearance, a number of health care workers infected by
needlestick exposure were studied for the presence of nAbs
during the acute phase of infection (Table 2) (17). All seven
individuals [numbered with respect to an earlier study (17)] were
infected by genotype 1 viruses and were screened for the
presence of nAbs to pseudotypes bearing genotype 1 HCV gps
(H77 and HCJ4) or MLV gp. Patient 1, who spontaneously
cleared HCV after 16 weeks of infection, failed to neutralize any
of the HCV pseudotypes tested (Table 2). In contrast, patient 5,
who cleared HCV after IFNribavirin therapy initiated at 36
weeks of infection, had nAb activity for HIV-HCV H77 at 15
weeks (Table 2). Of the remaining five patients who became
chronically infected, one (patient 4) had nAb activity detected at
93 weeks after infection for HIV-HCV H77 (Table 2). None of
the acute patient plasma samples neutralized HIV-MLV infec-
tivity. All patients seroconverted to HCV nonstructural antigens
between 2 and 9 weeks after infection; however, Abs to HCV
E1E2 gps were detected only in patients 4 and 5 coincident with
the detection of nAbs (data not shown). In conclusion, nAbs
were detected in only two of seven acutely infected individuals,
and their presence failed to associate with viral clearance. The
low frequency of individuals with crossreactive nAbs during the
early stages of infection contrasts markedly with that observed
during the chronic phase, suggesting that crossreactive nAbs
appear late during infection.
To address whether strain-specific nAbs develop, we studied
samples over a 26-year period from patient H who was infected
by blood transfusion in 1977 (18). HCV from this patient has
been used in multiple studies, including quasispecies measure-
ment, transmission, titration of infectivity in chimpanzees, and
the generation of an infectious molecular clone (19, 20). Both
strain H and the consensus molecular clone, H77, were obtained
from a plasma sample 7 weeks after infection. Sequential plasma
samples were tested for their ability to neutralize pseudotypes
bearing control MLV gp, autologous strain H and H77 gps, and
heterologous HCJ4 and HCJ6 HCV gps. None of the plasma
Table 1. Genotype-independent pattern of neutralization in chronic HCV infection
Neutralization of plasma from individuals infected with different HCV genotypes,* %
Infecting genotype
1a 1b 2a 2b 3a 4a
Patient
79
Patient
113
Patient
58
Patient
105
Patient
218
Patient
513
Patient
343
Patient
72
Patient
357
Patient
211
Patient
858
Patient
321
Patient
486
Patient
530
HIV-HCV H (1a) 95 74 92 92 92 93 53 91 90 87 95 86 – 97
HIV-HCV H77 (1a) 99 99 98 99 99 99 85 99 99 99 99 99 99 99
HIV-HCV HCJ4 (1b) 92 55 88 91 86 94 85 93 95 89 64 78 63 92
HIV-HCV HCJ6 (2a) 96 94 85 – 84 89 81 72 63 77 63 93 76 59
–, percentage neutralization 50%. Viral genotypes are listed in parentheses.
*All plasma samples were tested at a dilution of 1200.
Table 2. nAbs during acute HCV infection
Patient Week
Neutralization by plasma collected at
different times after infection,* %
HIV-HCV H77 HIV-HCV HCJ4
1 2 – –
7 – –
12 – –
17 – –
70 – –
112 – –
2 4 – –
11 – –
23 – –
64 – –
3 38 – –
81 – –
135 – –
260 – –
395 – –
4 6 – –
17 – –
59 – –
93 91 –
5 15 89 –
71 93 50
97 80 50
130 60 54
6 49 – –
80 – –
171 – –
572 – –
7 232 – –
316 – –
–, percentage neutralization 50%.
*All plasma samples were tested at a dilution of 1200.
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samples had significant neutralizing activity against HIV-MLV
(data not shown). nAbs specific for HIV-HCV H and H77 were
first detected at 7 weeks postinfection, coincident with acute
viremia and seroconversion (Fig. 2A) (18). nAbs capable of
inhibiting pseudotypes bearing heterologous HCJ4 and HCJ6
gps were first detected after 111 weeks of infection (Fig. 2 A and
data not shown). It should be noted that samples were not
available for study between 33 and 111 weeks after infection. The
neutralization titer of sequential plasma for HIV-HCV H77
increased over time, with the early, strain-specific response being
of low titer (ID90 of 1:100) and the later, more broadly crossre-
active response of higher titer (ID90 of 1:1,000–1:10,000) (Fig.
2B). The late appearance of crossreactive nAbs associated with
the first detectable IgG response to the E1E2 gps, in contrast to
the detection of an anti-NS3 IgG response at 14 weeks after
infection (Fig. 2C). A transient anti-E1E2 IgM response was
observed during the acute phase of infection that subsequently
declined to undetectable levels (Fig. 2C).
nAb Response in Experimentally Infected Chimpanzees. The chim-
panzee is the only available experimental system for HCV
vaccine studies. We studied the Ab response in 10 chimpanzees
infected with clonal H77 virus for neutralization of pseudotypes
bearing autologous (H77) and heterologous (HCJ4) gps. Three
of the animals spontaneously cleared virus infection, and sam-
ples from these animals at early (20 weeks) and late (100–213
weeks) times after infection failed to neutralize the HCV
pseudotypes tested (data not shown). Of the seven persistently
infected animals, six demonstrated nAbs detectable at various
times after infection (Fig. 3); samples from animal 6394 (55 and
77 weeks after infection) failed to neutralize any of the HCV
pseudotypes (data not shown). nAbs were generally detected
after the decline of viral RNA (Fig. 3) and alanine transferase
(ALT) (data not shown). All of the chimpanzees, with the
exception of 1535, failed to neutralize HIV-HCV HCJ4 (data not
shown). All plasma samples failed to show any effect on HIV-
MLV infectivity (data not shown). In general, there was an
association between the detection of a nAb response and the
detection of anti-E1E2 and anti-HVR Abs (Fig. 3). Indeed,
chimpanzee 6394, which failed to develop a nAb response, had
no detectable anti-E1E2 or anti-HVR Abs (data not shown).
Sequential plasma from chimpanzee 1629 showed reduced re-
activity with the HVR peptide and yet failed to show any
significant change in neutralization titer, suggesting that the nAb
response may not be specific for the HVR (Fig. 3). The intensity
(PN ratio) of the anti-E1E2 or anti-HVR Ab signal did not
appear to associate with neutralization titer, as demonstrated by
animal 6412, which had low levels of serologically detectable Ab
but similar nAb responses to the other infected animals.
The early nAb response was generally of low titer (ID50
1:250–1:500) and increased over time (ID50 1:1,000–1:4,000)
(data not shown). The majority of animals, even at late times
after infection, failed to neutralize pseudotype infectivity by
90%. For comparative purposes, the neutralization titer of
plasma from a number of chronically infected patients was
determined and found to be higher than samples from the
infected chimpanzees (Fig. 4; for clarity, data from two patients
are shown). In summary, animals that spontaneously cleared
virus infection failed to produce Abs capable of neutralizing
pseudotypes bearing autologous gps, suggesting that a nAb
response is not required for immune clearance of HCV. The
nAbs detected in six of the seven persistently infected animals
were generally of low titer and strain-specific, in contrast to that
observed in patient H at the same time after infection.
Discussion
In this study, we show that both strain-specific and crossreactive
nAb responses are elicited during HCV infection. The majority
of chronically infected patients have high-titer, crossreactive
nAb responses that develop late in the chronic phase of infection.
To understand whether these nAbs control viral replication, it
will be important to determine whether they neutralize
pseudotypes bearing autologous gps. Patient H developed nAbs
specific for pseudotypes bearing autologous gps after 7 weeks of
infection, coincident with acute viremia and seroconversion. In
contrast, Abs capable of neutralizing pseudotypes bearing het-
erologous gps were not detected until after 33 weeks of infection.
The appearance of the crossreactive nAb response in patient H
coincided with both an increase in neutralization titer and the
detection of an anti-E1E2 IgG response by enzyme immunoas-
say. In contrast, an anti-NS3 IgG response first was detected
after 14 weeks, during the acute phase of infection. A similar
delay in the appearance of gp-specific IgG responses during
acute HCV infection was reported recently (21), suggesting that
Fig. 2. Strain-specific and crossreactive nAb responses in patient H. (A)
Sequential plasma samples from chronically infected patient H were moni-
tored for their ability to neutralize pseudotype viruses bearing H77, H, and
HCJ4 gps at final dilution of 1200. Data are shown as percentage neutraliza-
tion. (B) Neutralization titer of plasma for HIV-HCV H77, defined as the
dilution of plasma able to reduce virus infectivity by 90%. (C) Plasma samples
(tested at a dilution of 1100) were tested for anti-NS3 (circle) and anti-E1E2
(square) IgM (open symbols) and IgG (filled symbols) responses. Data are
represented as a PN ratio, calculated by dividing the OD value of a test serum
by that obtained with an irrelevant HCV-negative human serum. PN values
2 were considered positive. All infections were performed in quadruplicate,
and the data are representative of two independent experiments.
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HCV may selectively delay the production of anti-gp-specific
Abs.
The majority of HCV infections are chronic; however, a
minority of individuals resolve their infection, suggesting that an
effective immune response can be mounted (17). Our study of
health care workers during the acute phase of infection suggests
that nAbs play a minimal role in viral clearance; however, we
were only surveying crossreactive Abs able to neutralize
pseudotypes bearing heterologous gps. The early appearance of
strain-specific nAbs in patient H suggests that nAbs may con-
tribute to the control viral replication, and further studies are
needed to clarify the role of strain-specific nAbs during acute
infection. The low frequency (two of seven) of individuals with
nAbs at 100 weeks after infection suggests that crossreactive
gp-specific nAb responses develop late in the chronic phase of
infection. The observation that the majority of chronically
infected individuals, presented here and in an independent study
of injection drug users (J.A.M. and B. Rehermann, unpublished
data), have crossreactive nAbs supports this interpretation.
nAb responses during viral infection generally are thought to
develop after the initial control of viremia (22, 23). However, the
presence of strain-specific nAb responses during seroconversion
in HCV and HIV (24) infection suggests that nAbs may help
control viral replication during the acute phase. Several obser-
vations support this conclusion. First, immunization of chim-
panzees to elicit HCV gp-specific Ab responses failed to induce
sterilizing immunity but induced a response that modulated
infection and reduced the rate of progression to chronic disease
(4, 25, 26). Second, nAb titers are associated with lack of disease
progression in long-term survivors during HIV infection (27).
Finally, HCV-infected patients with primary Ab deficiencies
have been reported to have accelerated rates of disease pro-
gression (28, 29). The lymphocytic choriomeningitis virus
(LCMV) murine model is often cited as an example of effective
cytotoxic T lymphocyte (CTL) control of a virus infection;
however, the kinetics of virus elimination do not always correlate
with development of a CTL response. Interestingly, when virus-
specific CD4 or CD8 T cell responses are low or ineffective,
LCMV may persist by evading the nAb response (30). It is likely
that both CTLs and nAbs play a role in the long-term control of
HCV infection, and, ideally, vaccines should elicit both crossre-
active nAb and cellular immune responses.
The chimpanzee model has been critical for the study of HCV
transmission and host immune response(s). nAbs were not
detected in any of the animals that resolved their infection,
suggesting a minimal role in viral clearance. However, strain-
specific nAb responses were observed in the majority of persis-
tently infected animals. One important difference between the
infected chimpanzees and humans is that the animals were
infected with a clonal source of virus, which may affect the
Fig. 3. The nAb response in experimentally infected chimpanzees. Sequential plasma samples from six chronically H77-virus-infected chimpanzees were
monitored for viral RNA levels, nAb for pseudotype virus bearing autologous H77 gp (HIV-HCV H77), and anti-E1E2 and anti-HVR reactivity. All plasma samples
were tested at a dilution of 1100. Data are shown as percentage neutralization. The anti-E1E2 and anti-HVR Ab data are represented as a PN ratio, calculated
by dividing the OD value of the test sera by that obtained with a preimmune serum. PN values 2 were considered positive. All assays were performed in
quadruplicate, and the data are representative of two independent experiments.
Logvinoff et al. PNAS  July 6, 2004  vol. 101  no. 27  10153
M
ED
IC
A
L
SC
IE
N
CE
S
breadth of the Ab response. Future experiments will address this
possibility by studying the nAb response in chimpanzees infected
with nonclonal virus quasispecies. The patterns of neutralization
observed in the chimpanzee are consistent with that seen in
patient H and may reflect an early, low-affinity IgM response
being replaced by an IgG response of higher affinity and
increased neutralization titer. Several reports suggest that HCV
gps are poorly immunogenic in infected chimpanzees, with low
levels of gp-specific Abs detected (31, 32). The comparison of
chimpanzee nAb responses to those observed in patient H
supports this conclusion, suggesting that the low-level nAb
response observed in the chimpanzees may reflect less immune
selection and explain the minimal variation observed in the
E1E2 region after clonal virus infection (16).
In summary, this study shows that HCV can induce Abs
capable of neutralizing retroviral pseudotypes bearing HCV gps.
The delayed appearance of a gp-specific IgG response, coinci-
dent with the detection of high-titer, crossreactive nAbs in
patient H, suggests that mechanisms may exist to prevent the
appearance of these Abs during acute infection. This observation
may result from inadequate T cell help, because several reports
indicate impairment of HCV-specific T cell function in patients
who fail to clear acute infection (reviewed in ref. 2). Although
nAb do not appear to be important in the resolution of acute
infection, their increasing titer and broadening reactivity during
chronic infection raises the possibility that they may contain
virus replication and modulate chronic disease.
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Fig. 4. Comparative neutralization titer of plasma from chronically infected
chimpanzees and patients. Plasma from chronically infected chimpanzees
1536, 6412, and 6475 collected at various weeks after infection (shown in
parentheses) and two patients, 79 and 513, were tested for their ability to
neutralize pseudotype virus bearing H77 gps (HIV-HCV H77). Data are shown
as percentage neutralization. All assays were performed in quadruplicate, and
the data are representative of two independent experiments.
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